Suppr超能文献

肝细胞癌的移植治疗:是否已达极限?

Transplantation for hepatocellular cancer: pushing to the limits?

作者信息

Lai Quirino, Vitale Alessandro

机构信息

General Surgery and Organ Transplantation Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy.

Department of Surgery, Oncology and Gastroenterology, Padua University, Padua, Italy.

出版信息

Transl Gastroenterol Hepatol. 2018 Sep 14;3:61. doi: 10.21037/tgh.2018.09.07. eCollection 2018.

Abstract

Milan criteria (MC) represents the cornerstone in the selection of patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT). MC represent the precursor of the scores based on the idea of "utility": in other terms, the scoring systems typically used in the field of LT oncology present the exclusive aim of selecting the cases with the best post-LT outcomes. However, some other scores have been proposed specifically investigating the risk of death or tumour progression during the waiting list. In this case, the selection process is connected with the idea of "priority": patients at higher risk for drop-out (DO) should be selected, prioritising them or, conversely, deciding to de-list them due to the high risk of post-LT futile transplant. Lastly, models based on the concept of "benefit", namely the balancing between priority and utility, have been recently created. The present review aims to examine these three different types of scoring systems, trying to underline their pro and cons in the allocation process of HCC patients.

摘要

米兰标准(MC)是肝细胞癌(HCC)患者等待肝移植(LT)时选择的基石。米兰标准是基于“效用”理念的评分系统的前身:换句话说,肝移植肿瘤学领域通常使用的评分系统的唯一目的是选择肝移植后预后最佳的病例。然而,已经提出了一些其他评分系统,专门研究等待名单期间的死亡风险或肿瘤进展风险。在这种情况下,选择过程与“优先级”的概念相关:应选择退出风险(DO)较高的患者,对他们进行优先排序,或者相反,由于肝移植后无效移植的高风险而决定将他们从名单中除名。最后,最近创建了基于“益处”概念的模型,即优先级和效用之间的平衡。本综述旨在研究这三种不同类型的评分系统,试图强调它们在肝癌患者分配过程中的优缺点。

相似文献

1
Transplantation for hepatocellular cancer: pushing to the limits?
Transl Gastroenterol Hepatol. 2018 Sep 14;3:61. doi: 10.21037/tgh.2018.09.07. eCollection 2018.
2
Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.
Transl Gastroenterol Hepatol. 2017 Sep 21;2:75. doi: 10.21037/tgh.2017.09.04. eCollection 2017.
3
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
4
Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
World J Gastroenterol. 2019 Oct 7;25(37):5687-5701. doi: 10.3748/wjg.v25.i37.5687.
5
Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.
Curr Treat Options Gastroenterol. 2017 Jun;15(2):296-304. doi: 10.1007/s11938-017-0133-3.
7
Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.
World J Hepatol. 2016 Jan 8;8(1):58-68. doi: 10.4254/wjh.v8.i1.58.
8
Hepatocellular Carcinoma and Liver Transplantation: State of the Art.
J Clin Transl Hepatol. 2014 Sep;2(3):176-81. doi: 10.14218/JCTH.2014.00013. Epub 2014 Sep 15.
9
Current challenges in liver transplantation for hepatocellular carcinoma.
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):867-79. doi: 10.1016/j.bpg.2014.08.001. Epub 2014 Aug 22.

引用本文的文献

1
New trends and perspectives in hepatobiliary surgery: preface.
Transl Gastroenterol Hepatol. 2018 Nov 30;3:99. doi: 10.21037/tgh.2018.11.06. eCollection 2018.

本文引用的文献

3
Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.
Transl Gastroenterol Hepatol. 2017 Sep 21;2:75. doi: 10.21037/tgh.2017.09.04. eCollection 2017.
4
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5.
6
Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer.
Hepatology. 2017 Dec;66(6):1910-1919. doi: 10.1002/hep.29342. Epub 2017 Nov 6.
8
Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
J Hepatol. 2017 Feb;66(2):374-381. doi: 10.1016/j.jhep.2016.10.008. Epub 2016 Oct 15.
9
Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
Ann Surg. 2017 Mar;265(3):557-564. doi: 10.1097/SLA.0000000000001966.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验